Metacrine’s FXR Program to be Highlighted in Three Abstracts at The Liver Meeting® 2017 in Washington, D.C.October 10, 2017
San Diego, CA - Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it will present three abstracts on its novel FXR agonist program at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in Washington, D.C. Metacrine has developed an industry leading and comprehensive FXR agonist program with over 1,300 novel chemical entities based on a unique non-bile acid chemical scaffold. MET409, which is highlighted in two of the three abstracts, is being developed as a best-in-class FXR agonist, with human clinical testing to be initiated in the first half of 2018.
Two abstracts, both on MET409 (#1980, #2026), titled “Efficacy of MET409, a potent, novel non-bile acid FXR agonist, in rodents and cynomolgus monkeys” and “Efficacy of the FXR agonist, MET409, in male and female mouse models of NASH and fibrosis” will be part of the poster session on Monday, October 23rd, 2017.
The third abstract (#1202), titled “Sex disparity in response of murine sclerosing cholangitis to short-term FXR agonist treatment” will be part of the poster session on Saturday, October 21st, 2017.
“We have developed a robust chemical portfolio of FXR agonists, which we view as a foundational target for non-alcoholic steatohepatitis (NASH),” said Ken Song, MD, President and CEO of Metacrine. “As we prepare to advance MET409 into clinical studies next year, we are optimistic on its prospects to have best-in-class efficacy and safety for NASH as well as other medical conditions.”
Metacrine is a privately held biotechnology company headquartered in San Diego, CA. The company is focused on efficiently developing innovative drugs that materially benefit patients with metabolic disease.BACK TO NEWS